Filing Details

Accession Number:
0001638599-19-000653
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-15 17:46:25
Reporting Period:
2019-07-11
Accepted Time:
2019-07-15 17:46:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682639 Eyenovia Inc. EYEN Pharmaceutical Preparations (2834) 471178401
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1728916 Tsontcho Ianchulev C/O Eyenovia, Inc.
295 Madison Avenue, Suite 2400
New York NY 10017
Chief Executive Officer Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $.0001 Acquisiton 2019-07-11 233,813 $2.78 426,248 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, Par Value $.0001 606,667 Indirect By Private Medical Equity, Inc.
Common Stock, Par Value $.0001 6,000 Indirect By The Meliora Trust
Common Stock, Par Value $.0001 453,333 Indirect By PME Investor Services Eyenovia, LLC
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (right to buy) $1.95 2027-07-07 267,370 267,370 Direct
Common Stock Stock Option (right to buy) $6.20 2028-07-24 124,210 124,210 Direct
Common Stock Stock Option (right to buy) $1.24 2015-03-23 2025-03-23 140,000 140,000 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2027-07-07 267,370 267,370 Direct
2028-07-24 124,210 124,210 Direct
2025-03-23 140,000 140,000 Indirect
Footnotes
  1. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  2. The option became exercisable as to 11,140 shares on August 7, 2017, and becomes exercisable in equal 11,140 share amounts on each of the 35 one-month anniversaries thereafter.
  3. This option is fully vested.